Kindred Biosciences, X-Body To Collaborate On Antibodies For Animal Health

(RTTNews) - Kindred Biosciences Inc (KIN), a development stage biopharmaceutical firm focused on pets, and X-Body Biosciences on Monday announced an alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, while Kindred Bio will develop and commercialize these antibodies.

Kindred Bio said it will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to Kindred Bio.

X-Body will use its proprietary DNA-antibody technology and live cell functional selection technology to generate therapeutic antibodies and Kindred Bio will develop these antibodies to address unmet medical needs in companion animal health.